The management of psoriasis

International Journal of Clinical Practice

Volumn 52, Issue 7, 1998, Pages 487-491

  Whittam, L R ^a,b   McGibbon, D H ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT;

FEMALE; HUMAN; MALE; MORBIDITY; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; REVIEW; TOPICAL DRUG ADMINISTRATION;

FEMALE; HUMANS; MALE; PSORIASIS; PUVA THERAPY;

EID: 0031788419     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Baker H, Ryan TJ. Generalised pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 1968; 80: 771.
2. Lazarus GS, Gilgor RS. Psoriasis, polymorphonuclear leukocytes and lithium carbonate: an important clue. Arch Dermatol 1979; 115: 1183-1184.
3. Pierard GE, Pierard-Franchimont C, de la Brassine M. Impetigo herpetiformis and pustular psoriasis during pregnancy. Am J Dermatopathol 1983; 5: 215-220.
4. Risum G. Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia. Br J Dermatol 1973; 89: 309-312.
5. Tiilikainen A, Lassu A, Karvonen J et al. Psoriasis and HLA-Cw6. Br J Dermatol 1980; 102: 179-184.
6. Tomfohrde J, Silverman A, Barnes R et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264: 1141-1145.
7. Trembath RC, Clough RL, Rosbotham JL et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Gen 1997; 6(5): 813-820.
8. Cooper KD. Skin infiltrating lymphocytes in normal and disordered skin: activation signals and functional roles in psoriasis and mycosis fungoides type cutaneous T cell lymphoma. J Dermatol 1992; 19: 731-737.
9. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
10. Higgins EM, du Vivier AWP. Alcohol abuse and treatment resistance in skin disease. J Am Acad Dermatol 1994; 30(6): 1048.
11. Lazar AP, Roenigk H Jr. Aids and psoriasis. Cutis 1987; 39: 347-351.
12. Lane AT, Wachs GN, Weston WL. Once-daily treatment of psoriasis with glucocorticosteroid ointments. J Am Acad Dermatol 1983; 8: 523-525.
13. Epstein NN, Epstein WL. Atrophic striae in patients with inguinal intertrigo: pathogenesis. Arch Dermatol 1963; 87: 450-457.
14. Perry HO, Soderstrom CW, Shulze RW. The Goeckerman treatment of psoriasis. Arch Dermatol 1968; 98: 178-182.
15. Marsico AR, Eaglstein WH, Weinstein GD. Ultraviolet light and tar in the Goeckerman treatment of psoriasis. Arch Dermatol 1976; 112: 1249-1251.
16. Kragballe K, Gjersten BT, De Hoop D et al. Double-blind, right/left control led comparison of calcipotriol and betamethasone valerate in the treatment of psoriasis vulgaris. Lancet 1991; 337: 988.
17. Kragballe K. Combination of topical calcipotriol and UVB radiation for psoriasis vulgaris. Dermatologica 1990; 181: 211-214.
18. Kercher M, Volkenandt M, Plewig G et al. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB. Lancet 1993; 342: 923.
19. Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogs. J Am Acad Dermatol 1992; 27: 1001-1008.
20. Ingram JT. The approach to psoriasis. BMJ 1953; 2: 591-594.
21. Marley WM, Henadez AD, Joseph JA et al. The effectiveness of low-strength anthralin in psoriasis. Arch Dermatol 1982; 118: 906-908.
22. Stratham BN, Rowell NR. Short contact dithranol therapy: twice daily and high concentration regimens. Br J Dermatol 1985; 113: 245-246.
23. Weelden van H, Baart de la Faille H, Young E et al. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988; 119: 11-19.
24. Gilmour JW, Vestey JP, Norval M. The effect of UV therapy on immune function in patients with psoriasis. Br J Dermatol 1993; 129: 28-38.
25. Parker S, Coburn P, Lawrence C et al. A randomised double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 1984; 110: 215-220.
26. Stem RS, Laird N, Melski J et al. Cutaneous squamous cell carcinoma in patients treated with PUVA. New Engl Med 1984; 310: 1156-1161.
27. Weinstein GD. Three decades of folic acid antagonists in dermatology (commentary). Arch Dermatol 1983; 119: 525-527.
28. Roenigk HH, Auerbach R, Maibach HI et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-156.
29. Boffa MJ, Smith A, Chalmers RJ et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135(4): 538-544.
30. van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 1997; 136(2): 275-278.
31. Granelli-Piperno A. In situ hybridisation for interleukin-2 and interleukin-2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med 1988; 168: 1649-1658.
32. Shupack J, Abel E, Bauer E et al. Cyclosporin as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997; 36: 423-432.
33. Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1997; 136: 527-530.
34. Zachariae H, Kragaballe K, Hansen HE et al. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997; 136: 531-535.
35. Lowe NJ, Wieder JM, Rosenbach A et al. Long-term low-dose cyclosporin therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710-719.
36. Layton AM, Sheenhan-Dare RA, Goodfield MJD et al. Hydroxyurea in the management of resistant psoriasis. Br J Dermatol 1989; 121: 647-653.
37. Dahl MHC, Comaish JS. Long-term effects of hydroxyurea in psoriasis. BMJ 1972; 4: 585-587.
38. Thune P. Treatment of palmoplantar psoriasis with Tigason. Dermatologica 1982; 164(1): 67-72.
39. Collins P, Rogers S. The efficacy of methotrexate in psoriasis: a review of 40 cases. Clin Exp Dermatol 1992; 17: 257.
40. Jaffe D, May LP, Sanchez M et al. Staphylococcal sepsis in HIV antibody seropositive psoriasis patients. J Am Acad Dermatol 1991; 24: 970-972.
41. Lazar AP, Roengik H Jr. Aids and psoriasis. Cutis 1987; 39: 347-351.
42. Meola T, Soter N, Ostreicher R et al. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol 1993; 29: 216-220.
43. Morison WL, Parrish JA, Bloch J et al. In vivo effects of UVB on lymphocyte function. Br J Dermatol 1979; 101: 513-519.
44. Duvic M, Rios A, Brewton GW et al. Remission of AIDS-associated psoriasis with zidovudine. Lancet 1987; ii: 627 (letter).
45. Thivolet J, Nicolas JF. Immunointervention in psoriasis with anti-CD4 antibodies, Int J Dermatol 1994; 33: 327-332.
46. Jegasothy BV, Ackerman CD, Todo S et al. Tacrolimus (FK 506): a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781-785.